Avidity Biosciences Inc (NASDAQ: RNA) on Monday, soared 3.95% from the previous trading day, before settling in for the closing price of $35.92. Within the past 52 weeks, RNA’s price has moved between $21.51 and $56.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -34.37%. The company achieved an average annual earnings per share of -36.62%. With a float of $109.72 million, this company’s outstanding shares have now reached $120.51 million.
Let’s determine the extent of company efficiency that accounts for 391 employees. In terms of profitability, gross margin is 92.3%, operating margin of -4853.44%, and the pretax margin is -4136.0%.
Avidity Biosciences Inc (RNA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Avidity Biosciences Inc is 8.98%, while institutional ownership is 107.54%. The most recent insider transaction that took place on Jun 17 ’25, was worth 27,549. In this transaction Chief Program Officer of this company sold 911 shares at a rate of $30.24, taking the stock ownership to the 50,392 shares. Before that another transaction happened on Jun 17 ’25, when Company’s Officer proposed sale 911 for $29.80, making the entire transaction worth $27,148.
Avidity Biosciences Inc (RNA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -36.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.18% during the next five years compared to -34.37% drop over the previous five years of trading.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
Avidity Biosciences Inc (RNA) is currently performing well based on its current performance indicators. A quick ratio of 16.91 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 504.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.01, a number that is poised to hit -0.96 in the next quarter and is forecasted to reach -4.40 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
Looking closely at Avidity Biosciences Inc (NASDAQ: RNA), its last 5-days average volume was 3.04 million, which is a jump from its year-to-date volume of 1.64 million. As of the previous 9 days, the stock’s Stochastic %D was 62.69%.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 90.51%, which indicates a significant increase from 75.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.92 in the past 14 days, which was lower than the 1.99 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $32.18, while its 200-day Moving Average is $33.61.
